John Krystal
Professor of Psychiatry
Data updated
Research Footprint
John Krystal appears in 21 tracked papers (2000–2025), most studied alongside Ketamine, Placebo and LSD, across Depressive Disorders, Major Depressive Disorder (MDD) and Healthy Volunteers.
Most-cited paper: Antidepressant effects of ketamine in depressed patients (3831 citations).
Frequent co-authors: Chadi Abdallah, Gerard Sanacora and Lauren Averill.
Publication Landscape
How the 21 papers Blossom tracks for John Krystal line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has John Krystal's publishing grown?
SourcedTracked papers by publication year; 2 earlier papers published before 2011. Click a year for the running total.
Don't read as total output: only the 21 of 21 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does John Krystal publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does John Krystal publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
John H. Krystal, MD, is a psychiatrist and neuroscientist based at Yale School of Medicine whose work bridges psychopharmacology, neuroimaging and clinical trials. He played an early and influential role in demonstrating the rapid antidepressant effects of subanaesthetic ketamine and has led and co‑authored multiple clinical studies and trials examining ketamine and other novel agents across mood, trauma-related and personality disorders. Krystal's research agenda combines experimental medicine approaches (including placebo‑controlled trials, open‑label and dose‑escalation designs) with multimodal neuroimaging to probe mechanisms of action and biomarkers of clinical response.
Key Impact
A leading clinician-scientist who helped translate NMDA-receptor antagonism into rapid-acting antidepressant treatments and who applies neuroimaging and translational methods to understand psychedelic and dissociative pharmacology.
Collaboration Network
27 collaborators· click a node to visit their profile
Full network →Collaboration Network
See John Krystal's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations John Krystal is associated with.
Yale School of Medicine Center for Brain Mind Health
academicThe Center for Brain and Mind Health at Yale School of Medicine bridges psychiatry and neuroscience, and is the institutional home of the Yale Program for Psychedelic Science. Both are directed by Christopher Pittenger, with Benjamin Kelmendi a central figure in the psychedelic studies. Yale's involvement is long-standing: serotonin's role in the action of LSD was first described here by George Aghajanian in the 1960s. Current work focuses on the psychological, neurobiological and therapeutic effects of psychedelics, with a notable strand examining psilocybin for obsessive-compulsive disorder, drawing on the group's clinical experience in Yale's OCD research clinic. The programme supports a broad, multidisciplinary community of investigators rather than a single treatment line.
View stakeholder →Yale University
academicIn 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
View stakeholder →